A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment (MCI)
Alzheimer Disease

Interventions

DRUG: Donanemab
DRUG: Aducanumab

Sponsor

Eli Lilly and Company